Exelixis and Daiichi Sankyo’s Minnebro (Esaxerenone) Receives MHLW Marketing Approval In Patients With Hypertension In Japan

 Exelixis and Daiichi Sankyo’s Minnebro (Esaxerenone) Receives MHLW Marketing Approval In Patients With Hypertension In Japan

Exelixis and Daiichi Sankyo’s Minnebro (Esaxerenone) Receives MHLW Marketing Approval In Patients With Hypertension In Japan

Shots:

  • The approval is based on P-III ESAX-HTN study assessing esaxerenone vs eplerenone for 12wks. in
    patients with essential hypertension, 1EP as SBP / DBP
  • In 2006, Exelixis and Daiichi Sankyo collaborated to develop and commercialize and Esaxerenone tablets. Exelixis will receive $20M milestone on sales and has received additional $20M as on regulatory milestones in Q1’18
  • Minnebro tablets (1.25/2.5/5 mg) are antihypertensives drug used for blocking mineralocorticoid receptor activation and is evaluated in P-III for diabetic nephropathy by Daiichi

Click here to read full press release/ article | Ref: Exelixis | Image: Yahoo 

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post